Biolas introduces VariClose in Europe


After the European launch in April 2015, Biolas has introduced the VariClose Vein Sealing Systems in the European market for the treatment of varicose veins.

“Using VariClose is easier, faster and more effective compared to current endovenous techniques. The absence of tumescent anaesthesia increases patient comfort and gives results that are easily visible once the glue has been administered,” notes Greg Fulton, consultant vascular surgeon at Cork University Hospital, Cork, Ireland.

“VariClose uses a sealing mechanism instead of fibrosis, used in other endovenous methods. I believe this increases the success rate and reduces complications related to fibrosis. This method can be the future of venous insufficiency treatment,” says Selçuk Gedik, Numune Training & Development Hospital, Ankara, Turkey.

“I believe the future of venous insufficiency treatment is shifting towards to non-ablative methods. VariClose offers a different and effective method. Potentially, this treatment can become the primary treatment in the guidelines in near future with long-term results,” adds Arkadiusz Jawien, University of Nicolai Copernicus, Bydgoszcz, Poland.

“The need for new treatment method for venous insufficiency was inevitable since the gold standard thermal ablation technologies are 15 years old now.  I believe VariClose will be the new gold standard for the treatment of varicose veins. Our system has been accepted very fast because of its performance, lower complication rate and easy treatment protocol. Right now treatment for venous insufficiency can be done during the lunch time easily and the patient can return to daily routine and work immediately without compression stocking,” states Rasit Dinc, CEO, Biolas.